7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle.

      Nature medicine
      Animals, Blotting, Western, Cell- and Tissue-Based Therapy, methods, Collagen, metabolism, Fibroblasts, Fluorescent Antibody Technique, Hydroxyproline, analysis, Immunohistochemistry, Matrix Metalloproteinase 9, Mice, Mice, Inbred C57BL, Muscle, Skeletal, blood supply, Muscular Dystrophy, Duchenne, therapy, Pregnancy Proteins, Reverse Transcriptase Polymerase Chain Reaction, Sarcoglycans, deficiency, Tendons, cytology

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sclerosis and reduced microvessel density characterize advanced stages of muscular dystrophy and hamper cell or gene delivery, precluding treatment of most individuals with Duchenne muscular dystrophy. Modified tendon fibroblasts expressing an angiogenic factor (placenta growth factor, PlGF) and a metalloproteinase (matrix metalloproteinase-9, MMP-9) are able to restore a vascular network and reduce collagen deposition, allowing efficient cell therapy in aged dystrophic mice. These data open the possibility of extending new therapies to currently untreatable individuals.

          Related collections

          Author and article information

          Comments

          Comment on this article